Skip to main content
. 2018 Aug 8;8(8):e021900. doi: 10.1136/bmjopen-2018-021900

Table 2.

Item distribution and missing data

Item Floor (%) Ceiling (%) Missing (%)
Patient-reported outcome
 Q.8 Problem related to health* 59.1 32.3 8.6
 Q.9 Mobility aids or assistive devices 0.1 0 11.5
 Q.10 Pain medications 3.0 14.6 12.3
 Q.11.1 Acute pain (activities) 0.7 33.1 12.8
 Q.11.2 Acute pain (interference) 0.3 33.2 12.8
 Q.12.1 Chronic pain (activities) 1.4 32.6 13.5
 Q.12.2 Chronic pain (interference) 0.1 33.6 13.5
 Q.13 Daily activities 0.1 42.4 14.3
 Q.14 Work/school life 0.1 27.8 21.8
 Q.15 Joint surgery or procedure 1.3 52.4 17.0
 Q.16 Comorbid diseases 0 56.1 0
Haemophilia-related health
 Q.17 Severity N/A N/A 17.3
 Q.18 Inhibitor status N/A N/A 19.1
 Q.19 Bleeding in the past 12 months 16.6 8.5 18.2
 Q.20 Bleeding in the past 2 weeks N/A N/A 18.9
 Q.21 Haemophilia treatment centre N/A N/A 19.4
 Q.25 Target joints N/A N/A 22.6
 Q. 26 Spontaneous joint bleeding N/A N/A 49.4
 Q.27 Limitation of range of motion* 66.6 11.4 22.0
 Q.28 Life-threatening or limb-threatening bleeding* 15.2 62.1 22.8
EQ-5D-5L and EQ-VAS
 Mobility 1.1 32.4 21.6
 Self-care 0.7 55.0 22.3
 Usual activities 0.7 37.9 22.4
 Pain/discomfort 1.1 23.9 22.9
 Anxiety/depression 1.6 37.3 22.8
 VAS 0 3.1 22.8

*Dichotomous outcome.

EQ-5D-5L, EuroQol five dimension 5-level instrument; EQ-VAS, EuroQol visual analogue scale; N/A, not applicable.